Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy CryoLife stock | 20.3

Own CryoLife stock in just a few minutes.

Posted

Fact checked

CryoLife, Inc is a medical devices business based in the US. CryoLife shares (CRY) are listed on the NYSE and all prices are listed in US Dollars. CryoLife employs 1,200 staff and has a trailing 12-month revenue of around USD$257.8 million.

How to buy shares in CryoLife

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for CryoLife. Find the stock by name or ticker symbol: CRY. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until CryoLife reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$20.3, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of CryoLife, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of CryoLife. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted CryoLife's share price?

Since the stock market crash in March caused by coronavirus, CryoLife's share price has had significant negative movement.

Its last market close was USD$20.3, which is 22.52% down on its pre-crash value of USD$26.2 and 60.73% up on the lowest point reached during the March crash when the shares fell as low as USD$12.63.

If you had bought USD$1,000 worth of CryoLife shares at the start of February 2020, those shares would have been worth USD$486.86 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$674.16.

CryoLife share price

Use our graph to track the performance of CRY stocks over time.

CryoLife shares at a glance

Information last updated 2020-10-20.
Latest market close USD$20.3
52-week range USD$12.63 - USD$31.39
50-day moving average USD$18.3863
200-day moving average USD$20.087
Wall St. target price USD$27.88
PE ratio 504
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.044

Buy CryoLife shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy CryoLife stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

CryoLife price performance over time

Historical closes compared with the close of $20.3 from 2020-11-16

1 week (2020-11-23) -2.73%
1 month (2020-10-30) 21.12%
3 months (2020-08-28) -0.93%
6 months (2020-05-29) -10.69%
1 year (2019-11-29) -17.91%
2 years (2018-11-30) -33.05%
3 years (2017-11-30) -0.25%
5 years (2015-11-30) 86.92%

Is CryoLife under- or over-valued?

Valuing CryoLife stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of CryoLife's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

CryoLife's P/E ratio

CryoLife's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 504x. In other words, CryoLife shares trade at around 504x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

CryoLife's PEG ratio

CryoLife's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 476.25. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into CryoLife's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

CryoLife's EBITDA

CryoLife's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$24.5 million.

The EBITDA is a measure of a CryoLife's overall financial performance and is widely used to measure a its profitability.

CryoLife financials

Revenue TTM USD$257.8 million
Operating margin TTM 2.03%
Gross profit TTM USD$183 million
Return on assets TTM 0.51%
Return on equity TTM -3.86%
Profit margin -4.33%
Book value $7.845
Market capitalisation USD$704.4 million

TTM: trailing 12 months

Shorting CryoLife shares

There are currently 3.9 million CryoLife shares held short by investors – that's known as CryoLife's "short interest". This figure is 7% down from 4.2 million last month.

There are a few different ways that this level of interest in shorting CryoLife shares can be evaluated.

CryoLife's "short interest ratio" (SIR)

CryoLife's "short interest ratio" (SIR) is the quantity of CryoLife shares currently shorted divided by the average quantity of CryoLife shares traded daily (recently around 409596.02094241). CryoLife's SIR currently stands at 9.55. In other words for every 100,000 CryoLife shares traded daily on the market, roughly 9550 shares are currently held short.

However CryoLife's short interest can also be evaluated against the total number of CryoLife shares, or, against the total number of tradable CryoLife shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CryoLife's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 CryoLife shares in existence, roughly 100 shares are currently held short) or 0.1272% of the tradable shares (for every 100,000 tradable CryoLife shares, roughly 127 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against CryoLife.

Find out more about how you can short CryoLife stock.

CryoLife share dividends

We're not expecting CryoLife to pay a dividend over the next 12 months.

Have CryoLife's shares ever split?

CryoLife's shares were split on a 3:2 basis on 28 December 2000. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your CryoLife shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for CryoLife shares which in turn could have impacted CryoLife's share price.

CryoLife share price volatility

Over the last 12 months, CryoLife's shares have ranged in value from as little as $12.63 up to $31.39. A popular way to gauge a stock's volatility is its "beta".

CRY.US volatility(beta: 1.32)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while CryoLife's is 1.3221. This would suggest that CryoLife's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

CryoLife overview

CryoLife, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS, a hybrid stent graft system. The company also provides E-xtra DESIGN ENGINEERING products, a range of stent graft systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G, a stent graft system for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac, a stent graft used to treat aneurysmal iliac arteries, as well as aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, it offers vascular preservation services; synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products, such as YAG laser consoles, related service and maintenance, and single-use, fiber-optic handpieces; and CryoVein femoral vein and CryoArtery femoral artery vascular preservation services for vascular access. The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. CryoLife, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site